Delta-fly pharma inc.: update on the r&d status of dfp-10917 and dfp-14927, a novel peg drug conjugate, in the patients with r/r aml

Tokushima, japan--(business wire)--following the previous information on june 30th in 2023, we are excited to share our latest development status. a phase iii study of dfp-10917 in patients with recurrent or refractory acute myeloid leukemia (r/r aml) at multicenter in the us is undergoing of the interim analysis. a phase i/ii study of dfp-10917 in the combination with venetoclax (vtx) in patients with r/r aml in the u.s. is in preparation. a patent has been granted in the u.s. for the combinat.
DAL Ratings Summary
DAL Quant Ranking